Engineered Native Bacteria Platform
Phenylketonuria (PKU)
Key Facts
About Endure Biotherapeutics
Endure Biotherapeutics, founded in 2020 and based in Cambridge, USA, is developing a proprietary platform using engineered native bacteria as durable live biotherapeutic products (LBTs). The core innovation involves isolating native bacteria from a host, genetically modifying them to produce therapeutic proteins, and re-administering them to engraft permanently in the gut, offering potential cures for metabolic and inflammatory diseases. The company is in the preclinical stage, led by a seasoned executive team, and its foundational technology has been validated in a peer-reviewed publication in *Cell*. EndureBio's strategy targets significant unmet needs in diseases like Phenylketonuria (PKU) and inflammatory bowel disease (IBD) by aiming for a one-time, curative treatment paradigm.
View full company profileAbout Endure Biotherapeutics
Endure Biotherapeutics, founded in 2020 and based in Cambridge, USA, is developing a proprietary platform using engineered native bacteria as durable live biotherapeutic products (LBTs). The core innovation involves isolating native bacteria from a host, genetically modifying them to produce therapeutic proteins, and re-administering them to engraft permanently in the gut, offering potential cures for metabolic and inflammatory diseases. The company is in the preclinical stage, led by a seasoned executive team, and its foundational technology has been validated in a peer-reviewed publication in *Cell*. EndureBio's strategy targets significant unmet needs in diseases like Phenylketonuria (PKU) and inflammatory bowel disease (IBD) by aiming for a one-time, curative treatment paradigm.
View full company profileAbout Endure Biotherapeutics
Endure Biotherapeutics, founded in 2020 and based in Cambridge, USA, is developing a proprietary platform using engineered native bacteria as durable live biotherapeutic products (LBTs). The core innovation involves isolating native bacteria from a host, genetically modifying them to produce therapeutic proteins, and re-administering them to engraft permanently in the gut, offering potential cures for metabolic and inflammatory diseases. The company is in the preclinical stage, led by a seasoned executive team, and its foundational technology has been validated in a peer-reviewed publication in *Cell*. EndureBio's strategy targets significant unmet needs in diseases like Phenylketonuria (PKU) and inflammatory bowel disease (IBD) by aiming for a one-time, curative treatment paradigm.
View full company profileTherapeutic Areas
Other Phenylketonuria (PKU) Drugs
| Drug | Company | Phase |
|---|---|---|
| SYNB1934 | Synlogic | Phase 3 |
| PKU Treatment | Cycle Pharmaceuticals | Commercial |
| NB-20X | Nerai Biosciences | Pre-clinical |
| NGGT002 | NGGT | Phase 1/2 (inferred) |
| SOM1311 | SOM Biotech | Preclinical |
| Repinatrabit | Otsuka | Open-Label Extension |
| PER303 | Perseo Pharma | Preclinical |
| JNT-517 | JCR Pharmaceuticals | Phase 1 |
| PALYNZIQ (pegvaliase-pqpz) | BioMarin Pharmaceutical | Approved/Marketed |
| PTC923 (sepiapterin) | PTC Therapeutics | Phase 3 |